Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To determine proportion of eyes with neovascular age-related macular degeneration (nAMD) with retinal fluid and central subfield thickness (CST) fluctuations and evaluate their impact on best-corrected visual acuity (BCVA) in eyes treated with the Port Delivery System with ranibizumab (PDS) versus monthly intravitreal ranibizumab injections.
Design: Post hoc analyses of phase 3 Archway trial (NCT03677934).
Participants: Adults with nAMD responsive to anti-VEGF therapy.
Intervention: Four hundred eighteen patients randomized 3:2 to the PDS (100 mg/mL) with refill-exchanges every 24 weeks (Q24W) or monthly intravitreal ranibizumab (0.5 mg) for 96 weeks.
Outcomes: Proportion of eyes in each treatment arm with subretinal and/or intraretinal fluid (SRF/IRF) overall and in central 1 mm; BCVA changes from baseline by treatment arm and fluid presence/location; proportion of eyes with CST fluctuations from baseline to week 48, week 48 to 96, and baseline to week 96; effects of CST fluctuations on BCVA.
Results: Four hundred fifteen eyes were assessed. In the PDS versus monthly ranibizumab arm, proportion of eyes with SRF/IRF, central SRF, and central IRF were 47.6% versus 50.9%, 29.0% versus 19.2%, and 11.7% versus 12.6% at baseline, and 57.8% versus 56.1%, 21.6% versus 14.8%, and 7.0% versus 8.4% at week 96, respectively. BCVA changes from baseline to week 96 were -1.1 letters with the PDS versus -1.4 with monthly ranibizumab in eyes with SRF/IRF, and -1.9 versus -1.8 in eyes with central SRF. In eyes with central IRF, BCVA changes from baseline to week 96 were -2.1 with the PDS versus -6.9 with monthly ranibizumab, respectively (mean BCVA at 96 weeks 68.9 [20/40] vs. 64.6 [20/50]). CST fluctuations occurred in 32.1% and 29.7% of PDS versus monthly ranibizumab eyes; corresponding BCVA changes from baseline to week 96 were -2.5 versus -2.6 (mean BCVA at 96 weeks 72.7 [20/35] vs. 71.5 [20/38]).
Conclusions: Port Delivery System with ranibizumab Q24W maintained BCVA to 96 weeks regardless of SRF/IRF, central SRF, central IRF, or CST fluctuations, comparable with monthly ranibizumab, thus supporting the use of the PDS in stabilizing retinal anatomy without the need for monthly treatment in patients with nAMD.
Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.oret.2024.10.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Morphologic changes of the double-layer sign during anti-vascular endothelial growth factor therapy in eyes with neovascular age-related macular degeneration.
Int Ophthalmol
August 2025
Hikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-BuildingKita-ku, Sapporo, 060-0807, Japan.
Purpose: To evaluate longitudinal morphologic changes of the double-layer sign (DLS) on optical coherence tomography (OCT) in eyes with neovascular age-related macular degeneration (nAMD) presenting with exudative macular neovascularization (eMNV) undergoing anti-vascular endothelial growth factor (VEGF) therapy.
Methods: This retrospective study included 207 consecutive treatment-naïve eyes (207 patients) with nAMD presenting with eMNV and a DLS treated with intravitreal anti-VEGF injections and were followed for ≥ 12 months. All eyes received 3 monthly loading injections followed by either treat-and-extend (TAE) or pro re nata (PRN) retreatment, per predefined criteria.
Influence of Retinal Venous Pressure on Visual and Structural Outcomes in Eyes with Central Retinal Vein Occlusion Undergoing Anti-VEGF Treatment.
Clin Ophthalmol
August 2025
Department of Ophthalmology, the First Hospital of China Medical University, Shenyang, People's Republic of China.
Purpose: This study investigates the role of retinal venous pressure (RVP) in determining visual and anatomical outcomes in eyes affected by macular edema (ME) secondary to central retinal vein occlusion (CRVO) and treated with anti-vascular endothelial growth factor (VEGF) therapy.
Methods: A retrospective observational study analyzed data from 31 eyes of 31 patients with CRVO-induced ME. RVP was quantified using an ophthalmodynamometer, and participants were divided into two cohorts: low RVP (19 eyes) and high RVP (12 eyes).
One-year results of visual response following intravitreal novel anti-VEGF injection for diabetic macular edema in a Latino population.
Int J Retina Vitreous
August 2025
Regional Medical Affairs Department, Laboratorios Sophia, S.A. de C.V., Paseo del Norte 5255, Guadalajara Technology Park, Zapopan, Jalisco, 45010, Mexico.
Background: Diabetic macular edema (DME) is a leading cause of vision impairment. This study evaluated the effects of multiple anti-VEGF intravitreal injections, including a novel anti-VEGF PRO-169, on best-corrected visual acuity (BCVA) and central macular thickness (CMT) in Latino patients with DME.
Methods: This is a multicenter, drug-agnostic interim analysis.
Efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration - 6 month results after completion of the loading phase.
Graefes Arch Clin Exp Ophthalmol
July 2025
Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, Germany.
Purpose: To report the efficacy and durability of switching treatment to faricimab in recalcitrant neovascular age-related macular degeneration (nAMD) at six months after completion of the loading phase (nine months after switching).
Methods: Recalcitrant nAMD was defined as persistent fluid despite monthly injections (q4w) or inability to extend treatment intervals beyond six weeks (q6w). The study included patients on a treat & extend regimen for six months after three monthly injections.
Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial.
Br J Ophthalmol
July 2025
Department of Ophthalmology, Goethe-Universitat Frankfurt am Main, Frankfurt am Main, Germany.
Background/aims: To compare fluctuations of central subfield retinal thickness (CSRT) in patients with neovascular age-related macular degeneration undergoing ranibizumab pro re nata versus aflibercept bimonthly treatment in a prospective 12 month, phase IV, randomised, multicentre study.
Methods: Ranibizumab was administered according to best-corrected visual acuity (BCVA) and/or disease activity detected on spectral domain optical coherence tomography. Aflibercept was administered at three initial monthly visits followed by bimonthly treatment.